- Home
- AAP vs GERN Comparison
AAP vs GERN Comparison
Compare AAP & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AAP
- GERN
- Stock Information
- Founded
- AAP 1929
- GERN 1990
- Country
- AAP United States
- GERN United States
- Employees
- AAP N/A
- GERN N/A
- Industry
- AAP Auto & Home Supply Stores
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- AAP Consumer Discretionary
- GERN Health Care
- Exchange
- AAP Nasdaq
- GERN Nasdaq
- Market Cap
- AAP 2.8B
- GERN 2.5B
- IPO Year
- AAP N/A
- GERN 1996
- Fundamental
- Price
- AAP $45.94
- GERN $2.89
- Analyst Decision
- AAP Hold
- GERN Strong Buy
- Analyst Count
- AAP 15
- GERN 10
- Target Price
- AAP $46.40
- GERN $7.15
- AVG Volume (30 Days)
- AAP 1.8M
- GERN 14.8M
- Earning Date
- AAP 02-26-2025
- GERN 02-26-2025
- Dividend Yield
- AAP 2.18%
- GERN N/A
- EPS Growth
- AAP N/A
- GERN N/A
- EPS
- AAP 0.73
- GERN N/A
- Revenue
- AAP $11,191,239,000.00
- GERN $29,480,000.00
- Revenue This Year
- AAP N/A
- GERN $31,478.06
- Revenue Next Year
- AAP N/A
- GERN $290.89
- P/E Ratio
- AAP $58.20
- GERN N/A
- Revenue Growth
- AAP 15.75
- GERN 9199.68
- 52 Week Low
- AAP $35.59
- GERN $1.64
- 52 Week High
- AAP $88.56
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- AAP 54.70
- GERN 25.84
- Support Level
- AAP $43.71
- GERN $2.80
- Resistance Level
- AAP $46.47
- GERN $3.68
- Average True Range (ATR)
- AAP 2.10
- GERN 0.18
- MACD
- AAP -0.20
- GERN -0.04
- Stochastic Oscillator
- AAP 41.88
- GERN 10.23
About AAP Advance Auto Parts Inc.
Advance Auto Parts is a leading auto parts retailer in North America with more than 4,000 store and branch locations. About 55% of the firm's sales are geared toward the professional channel, with the remaining 45% going to the do-it-yourself market. Through its vast store footprint and distribution network, Advance manages thousands of stock-keeping units conducive to various vehicle makes and models. The retailer primarily competes on the basis of inventory availability and service speed, making the operating efficiency of its hub and spoke distribution model critical to meeting customer needs.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.